Abstract
The immune system protects organisms from pathogens. The immune cells, in particular T- and B-lymphocytes, develop and acquire effector functions in specialized tissues called the lymphoid organs. The lymphoid organs exhibit lower oxygen tensions than the blood or the atmosphere. Furthermore, inflammatory and tumor environments where lymphocytes execute effector functions also have very low oxygen tensions. These findings led to the hypothesis that lymphocytes may have evolved adaptive mechanisms to function under hypoxic conditions. Cellular responses to hypoxia are triggered by the hypoxia inducible factor-1α (HIF-1α). In this paper we review the development and function of T- and B-lymphocytes in the absence HIF-1a. Our studies suggest that HIF-1α deficiency depresses the function of cytotoxic T-lymphocytes and blocks B-cell development in the bone marrow. B1 lymphocytes of fetal origin, on the other hand, accumulate and may produce auto-antibodies and autoimmunity.
Keywords: hif-, t-lymphocyte, b-lymphocyte, lymphocyte development
Current Pharmaceutical Design
Title: HIF-1α Deficiency Perturbs T and B Cell Functions
Volume: 9 Issue: 23
Author(s): Hidefumi Kojima, Michail V. Sitkovsky and Marilia Cascalho
Affiliation:
Keywords: hif-, t-lymphocyte, b-lymphocyte, lymphocyte development
Abstract: The immune system protects organisms from pathogens. The immune cells, in particular T- and B-lymphocytes, develop and acquire effector functions in specialized tissues called the lymphoid organs. The lymphoid organs exhibit lower oxygen tensions than the blood or the atmosphere. Furthermore, inflammatory and tumor environments where lymphocytes execute effector functions also have very low oxygen tensions. These findings led to the hypothesis that lymphocytes may have evolved adaptive mechanisms to function under hypoxic conditions. Cellular responses to hypoxia are triggered by the hypoxia inducible factor-1α (HIF-1α). In this paper we review the development and function of T- and B-lymphocytes in the absence HIF-1a. Our studies suggest that HIF-1α deficiency depresses the function of cytotoxic T-lymphocytes and blocks B-cell development in the bone marrow. B1 lymphocytes of fetal origin, on the other hand, accumulate and may produce auto-antibodies and autoimmunity.
Export Options
About this article
Cite this article as:
Kojima Hidefumi, Sitkovsky V. Michail and Cascalho Marilia, HIF-1α Deficiency Perturbs T and B Cell Functions, Current Pharmaceutical Design 2003; 9 (23) . https://dx.doi.org/10.2174/1381612033454388
DOI https://dx.doi.org/10.2174/1381612033454388 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Modulation of Cell Death in Age-Related Diseases
Current Pharmaceutical Design Immunosuppressive Therapy for Myelodysplastic Syndromes
Current Pharmaceutical Design Gene Therapeutic Approaches for Immune Modulation in AIDS
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Targeting Kruppel-Like Factor 5 (KLF5) for Cancer Therapy
Current Topics in Medicinal Chemistry Status of Flavonols as P-Glycoprotein Inhibitors in Cancer Chemotherapy
Current Cancer Therapy Reviews Targeting DNA Minor Groove by Hybrid Molecules as Anticancer Agents
Current Medicinal Chemistry Chemical Advances in Therapeutic Application of Exosomes and Liposomes
Current Medicinal Chemistry Design of Lipophilic Prodrugs to Improve Drug Delivery and Efficacy
Current Drug Targets Recombinant Human Serum Albumin Fusion Proteins and Novel Applications in Drug Delivery and Therapy
Current Pharmaceutical Design Cancer Stem Cells and their Management in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Translational Gap in Glioma Research
Anti-Cancer Agents in Medicinal Chemistry Targeted Therapies in the Treatment of Advanced Renal Cell Carcinoma
Recent Patents on Anti-Cancer Drug Discovery Cancer Therapy: Targeting Mitochondria and other Sub-cellular Organelles
Current Pharmaceutical Design Targeting Histone Deacetylases for the Treatment of Immune, Endocrine & Metabolic Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets Regulation of HIPK Proteins by MicroRNAs
MicroRNA Therapeutic Targets in Triple Negative Breast Cancer - Where are we now?
Recent Patents on Anti-Cancer Drug Discovery It Takes Two to Tango: The Structure and Function of LIM, RING, PHD and MYND Domains
Current Pharmaceutical Design Eriocalyxin B-Induced Apoptosis in Pancreatic Adenocarcinoma Cells Through Thiol-Containing Antioxidant Systems and Downstream Signalling Pathways
Current Molecular Medicine Melanoma Immunotherapy: Past, Present, and Future
Current Pharmaceutical Design Notch-Associated MicroRNAs in Cancer
Current Drug Targets